(AOF) – Sensorion announces the completion of a placement for a gross amount of 15 million euros reserved for specific categories of investors, through the issue of 24.57 million ordinary shares by the company, at a price per new share of 0.63 euros for the benefit of existing shareholders including Redmile Group, Invus, Sofinnova Partners and a major investment management company. Settlement and delivery of the Private Placement should take place around April 11, 2024, subject to the usual conditions.
The pioneering clinical-stage biotechnology company, dedicated to the development of innovative therapies to restore, treat and prevent hearing loss, has also indicated that it is extending its cash horizon until the end of 2025.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.